Back to all news

ZYUS Life Sciences Strengthens Expertise of Clinical Advisory Committee with the Appointment of Audrey Haukioja

Mar. 18, 2021

Ms. Haukioja will leverage more than 25 years of progressive pharmaceutical experience to provide strategic guidance to ZYUS’ clinical trial programs

SASKATOON, Saskatchewan--(BUSINESS WIRE)-- ZYUS Life Sciences Inc. ("ZYUS"), a Canadian life sciences company leading scientific research and development in phyto-therapeutics, is pleased to announce the appointment of Audrey Haukioja to its Clinical Advisory Committee, which provides strategic guidance to ZYUS’ clinical trial programs. Ms. Haukioja has more than 25 years of experience in the pharmaceutical industry, bringing significant global expertise on drug development and executive leadership. This announcement further supports ZYUS’ clinical development strategy to pioneer the next generation of life sciences through an evidence-based approach.

As with her Clinical Advisory Committee peers, Ms. Haukioja brings tremendous medical leadership and expertise to her new advisory role with ZYUS. She is a results-driven executive who has worked in the pharmaceutical field, specifically in the area of clinical trials and drug development, for the entirety of her 25+ year career, holding Canadian, Regional and Global positions at Glaxo Canada and Hoffmann-La Roche Limited including leadership of world-wide Pharma Development Operations for Roche. For the past five years, she has established her own independent consulting company to offer services to leaders both nationally and internationally, in disciplines including pre-clinical and clinical development, drug and organizational development, strategic planning, and executive mentoring. Her experience will have direct positive impacts and influence on clinical trials undertaken by ZYUS to verify the efficacy of its cannabinoid formulations.

“Our Clinical Advisory Committee provides added mentorship, expertise and guidance to help ensure the success of ZYUS’ research and clinical trial programs, and the new appointment of Ms. Haukioja to the Committee strengthens this brilliant team of proven leaders,” said ZYUS CEO Brent Zettl. “We are excited to welcome Audrey, along with her vast experience and leadership in clinical trial development and management, to help ZYUS further improve quality of life for patients.”

Ms. Haukioja joins previously-appointed Advisory Committee members: ZYUS’ Chief Medical Officer, Dr. Lionel Marks de Chabris, Chair of the Committee; Dr. Mary Lynch, Director of Research at the Pain Management Unit at the Queen Elizabeth II Health Sciences Centre; Dr. David J. Shulkin, former ninth Secretary of the US Department of Veterans Affairs and Under Secretary of Health under President Obama; Dr. Cedric Francois, Co-Founder, Chief Executive Officer and President of Apellis Pharmaceuticals; and, Dr. Alice Zwerling, Assistant Professor in the School of Epidemiology and Public Health in the Faculty of Medicine at the University of Ottawa. Ms. Haukioja will join the Clinical Advisory Committee in providing senior medical, clinical, and scientific input and guidance on our clinical trial programs. The addition of Ms. Haukioja adds global pharmascience expertise to the committee and underscores ZYUS’ commitment to inclusion and diversity in the workplace.

About ZYUS Life Sciences Inc.

ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of innovative cannabinoid-based therapeutics and product candidates. Through clinical research and IP development, we intend to deliver high-quality oils, soft gels, topical creams and other cannabinoid-based therapeutics and product candidates to patients worldwide. The ZYUS vision is to elevate cannabinoids as a standard of care and expand the potential of protein-based formulations in pursuit of a transformational impact on patients’ lives. ZYUS: Advancing the Science of Well-Being. Visit

Forward-Looking Information

This news release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of ZYUS to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These forward-looking statements include, but are not limited to expectations with respect to our business plans, research activities and product lines. Research and clinical trial programs are of an experimental nature and no particular results can be guaranteed due to a number of factors and risks.

Often, but not always, forward-looking statements can be identified by the use of words such as “expects,” “expected,” “expectation,” “anticipates,” “believes,” “intends,” “estimates,” “predicts,” “continues,” “potential,” “targeted,” “plans,” “possible” and similar expressions, or statements that events, conditions or results “will,” “may,” “could,” “would” or “should” occur or be achieved, or the negative of these terms or other comparable terminology. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.

Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.

Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. ZYUS does not assume any obligation to update or revise any forward-looking statements or information respecting the proposed research or results therefrom, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

ZYUS Media Inquiries

ZYUS Investor Relations
Bruce M. Mann

Source: ZYUS Life Sciences Inc.

Multimedia Files: